Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Down 4.5%

Shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) dropped 4.5% on Wednesday . The stock traded as low as $3.35 and last traded at $3.60. Approximately 159,929 shares changed hands during trading, an increase of 365% from the average daily volume of 34,393 shares. The stock had previously closed at $3.77.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of Phio Pharmaceuticals in a research note on Tuesday, May 14th.

Phio Pharmaceuticals Trading Up 3.6 %

The company has a 50 day simple moving average of $5.92 and a 200-day simple moving average of $6.43. The stock has a market cap of $2.03 million, a price-to-earnings ratio of -0.14 and a beta of 1.45.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings results on Thursday, May 9th. The company reported ($4.23) earnings per share (EPS) for the quarter. Equities analysts forecast that Phio Pharmaceuticals Corp. will post -16.38 earnings per share for the current fiscal year.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.